Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Latest News about Eisai Co Ltd
Recent news which mentions Eisai Co Ltd
Bristol Myers Squibb says Alzheimer's is the biggest market for new schizophrenia drug
January 15, 2025
Tags
Business
US: News
Health & Science
From
CNBC.com News
Biogen tops estimates, raises profit guidance as Alzheimer's drug Leqembi gains traction
October 30, 2024
Tags
US: News
Business
Pharmaceuticals
From
CNBC.com News
5 things to know before the stock market opens Monday
September 09, 2024
Tags
Investment strategy
Norfolk Southern Corp
General Motors Co
From
CNBC.com News
Alzheimer's drug Leqembi promises to give patients more time, but they face a long road to treatment
September 08, 2024
Tags
Biotechnology
Companies
Breaking news
From
CNBC.com News
Patients on Alzheimer's drug Leqembi see benefits over three years, Eisai study says
July 30, 2024
Tags
Health care industry
Biotech and Pharmaceuticals
Business News
From
CNBC.com News
Older GLP-1 drug from Novo Nordisk may slow Alzheimer's disease progression by protecting the brain, study says
July 30, 2024
Tags
Biogen Inc
Business News
Biotech and Pharmaceuticals
From
CNBC.com News
European drug regulator rejects Alzheimer's treatment Leqembi from Biogen, Eisai
July 26, 2024
Tags
Eisai Co Ltd
Companies
Biotechnology
From
CNBC.com News
Jim Cramer says Eli Lilly isn't a 'one trick pony' after FDA advisers endorse its Alzheimer's drug
June 11, 2024
Tags
U/S/ Markets
Biogen Inc
Investing
From
CNBC.com News
Biogen tops quarterly profit estimates as cost cuts take hold, Leqembi launch picks up
April 24, 2024
Tags
Breaking news
Biogen Inc
Companies
From
CNBC.com News
Eli Lilly says FDA delays approval of Alzheimer's drug in surprise move
March 08, 2024
Tags
Pharmaceuticals
Eli Lilly and Co
Health care industry
From
CNBC.com News
Healthy Returns: The launch of breakthrough Alzheimer’s drug Leqembi is off to a slow start
February 20, 2024
Tags
Health care industry
Science
Health & Science
From
CNBC.com News
Biogen revenue and profit shrink on Aduhelm costs, slumping sales of multiple sclerosis therapies
February 13, 2024
Tags
Pharmaceuticals
Health care industry
Health & Science
From
CNBC.com News
Biogen drops controversial Alzheimer's drug Aduhelm to focus on Leqembi, experimental treatments
January 31, 2024
Tags
Business News
Social issues
Biogen Inc
From
CNBC.com News
Weight loss drugs, Alzheimer's treatments and gene editing: Enormous firsts defined 2023 in pharma
December 20, 2023
Tags
Biotech and Pharmaceuticals
Health care industry
Biogen Inc
From
CNBC.com News
Pfizer's twice-daily weight loss pill joins a long list of obesity drug flops
December 02, 2023
Tags
Business
US: News
Sanofi SA
From
CNBC.com News
More convenient form of breakthrough Alzheimer's drug Leqembi shows promising results in study
October 25, 2023
Tags
Pharmaceuticals
Health & Science
Science
From
CNBC.com News
5 things to know before the stock market opens Tuesday
July 18, 2023
Tags
Business
Investment strategy
Eli Lilly and Co
From
CNBC.com News
Eli Lilly expects FDA decision on Alzheimer's treatment donanemab by the end of the year
July 17, 2023
Tags
Breaking news
Companies
Biotechnology
From
CNBC.com News
Medicare will pay for Alzheimer's drug Leqembi. What patients and doctors should know
July 08, 2023
Tags
Health & Science
Science
US: News
From
CNBC.com News
Sales of Alzheimer’s drug Leqembi may be slow initially but could pick up in 2024
July 07, 2023
Tags
Companies
Biotechnology
Eisai Co Ltd
From
CNBC.com News
Stocks making the biggest moves midday: Rivian, Levi Strauss, Biogen, First Solar and more
July 07, 2023
Tags
Alibaba Group Holding Ltd
Rivian Automotive Inc
Levi Strauss & Co
From
CNBC.com News
Japanese pharma Eisai slides 4% despite FDA approval for Alzheimer's drug
July 07, 2023
Tags
Biotech and Pharmaceuticals
Asia Markets
Pharmaceuticals
From
CNBC.com News
FDA approves Alzheimer’s drug Leqembi, paving way for broader Medicare coverage
July 06, 2023
Tags
Alzheimer's disease
Biotech and Pharmaceuticals
Health care industry
From
CNBC.com News
FDA advisors to weigh whether Alzheimer's drug Leqembi should receive full approval
June 09, 2023
Tags
Eisai Co Ltd
Policy
Breaking News: Business
From
CNBC.com News
Bernie Sanders says price of Alzheimer's treatment is unconscionable, calls on HHS to take action
June 07, 2023
Tags
US: News
Business
Health & Science
From
CNBC.com News
Alzheimer's treatment Leqembi could cost Medicare up to $5 billion per year, study estimates
May 12, 2023
Tags
Policy
Eisai Co Ltd
Breaking News: Business
From
CNBC.com News
Bipartisan attorneys general call on Medicare to cover Alzheimer's treatments
May 01, 2023
Tags
Health care industry
US Economy
US Top News and Analysis
From
CNBC.com News
Alzheimer’s patients may wait years to get treated with new drugs, putting them at risk of more severe disease
April 30, 2023
Tags
Biotech and Pharmaceuticals
US Top News and Analysis
Biogen Inc
From
CNBC.com News
Alzheimer's: Medicare will cover Leqembi for all patients if FDA approves drug, CMS chief says
April 26, 2023
Tags
Congress
Health care industry
Biotech and Pharmaceuticals
From
CNBC.com News
Biogen isn't concerned about competing with Eli Lilly in the Alzheimer’s drug space, CEO says
April 25, 2023
Tags
Alzheimer's disease
Biotech and Pharmaceuticals
Health care industry
From
CNBC.com News
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.